Form 4: Lifecore Biomedical Director to Acquire 19,506 Shares via RSU Grant

Lifecore Biomedical, Inc. Director Humberto Calheiros Antunes is reported to acquire 19,506 shares of common stock through a restricted stock unit grant on July 15, 2025, increasing his beneficial ownership to 47,060 shares.

Summary

• Humberto Calheiros Antunes, a Director of Lifecore Biomedical, Inc. (LFCR), is reported to acquire 19,506 shares of common stock.
• The reported transaction date for this acquisition is July 15, 2025.
• These shares are restricted stock units (RSUs) that convert on a 1-for-1 basis to common stock.
• Following this future transaction, Antunes is reported to beneficially own a total of 47,060 shares of Lifecore Biomedical, Inc. common stock.
• The RSUs are set to vest on the earlier of the one-year anniversary of the grant date (July 15, 2025) or the date of the company's annual meeting of stockholders in calendar year 2026, provided that meeting is at least 50 weeks from the grant date.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director indicates ongoing compensation and alignment of interests, which is generally positive. However, the transaction date being in the future and it being a grant rather than an open-market purchase slightly tempers the immediate positive sentiment.

Positives

• The grant of restricted stock units to a director aligns their interests with long-term shareholder value.
• An increase in a director's beneficial ownership can signal confidence in the company's future prospects.

Negatives

• The acquisition is through a grant of restricted stock units, not a direct open-market purchase, meaning no immediate cash investment by the director.

Risks

• The value of the acquired shares is subject to market fluctuations.
• The shares are restricted stock units and are subject to vesting conditions, meaning they are not immediately fully owned and could be forfeited if conditions are not met.
• The reported transaction date of July 15, 2025, is in the future, which is unusual for a Form 4 filing that typically reports past transactions.

Future Outlook

The vesting schedule for the restricted stock units indicates future ownership of shares for the director, which is intended to align their interests with the company's long-term performance and strategic goals.

Industry Context

This is a company-specific insider transaction related to director compensation and equity ownership, and does not directly reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to equity ownership.

Next Steps

• The vesting of the restricted stock units on the earlier of July 15, 2026, or the 2026 annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Lifecore Biomedical, LFCR, SEC Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership